The launch of NasaDose Ultra Soft Unit Dose Spray further strengthens Bespak’s expanded nasal drug delivery offering. It follows Bespak’s recently announced collaboration with Upperton, a specialist formulation development CDMO, which brings together expertise in formulation, device engineering, clinical supply and commercial manufacture. Together with specialist technologies from partners including Resyca, the offering supports liquid, soft mist and dry powder nasal products from early development through to commercial supply.

The NasaDose Ultra Soft Unit Dose Spray combines, for the first time, differentiated drug delivery technologies from Bespak and Resyca to create a unique intranasal delivery solution for gentle yet precise nasal delivery. Resyca’s soft mist technology generates a fine, low-velocity nasal spray providing consistent aerosol performance with low mechanical shear, supporting the delivery of sensitive and complex formulations. Bespak’s spring-powered actuation mechanism is engineered to deliver a repeatable dose largely independent of user actuation speed, reducing operator variability and supporting consistent performance. The device allows key performance parameters, including spray characteristics, dose volume and actuation force, to be configured according to formulation requirements and target patient populations, and enables precise and controlled deposition within the nasal cavity, including targeted delivery to the turbinate and olfactory regions. 

The NasaDose Ultra Soft Unit Dose Spray is designed to support the delivery of both conventional small molecules and formulations including proteins, peptides and other complex biologics that may be susceptible to degradation during aerosolisation, making it suitable for applications including local nasal therapies, prophylaxis, vaccines and systemic delivery, with particular potential for nose-to-brain and CNS therapies. 

Chris Hirst, CEO of Bespak said: “Nasal drug delivery is an exciting and rapidly evolving area, with developers exploring new ways to deliver increasingly complex therapies. NasaDose Ultra Soft Unit Dose Spray brings together our established NasaDose platform with Resyca’s proprietary soft mist technology, expanding the options available to customers developing the next generation of nasal therapies. Combined with our growing formulation and development capabilities, this gives customers a strong platform to progress promising nasal drug products from early development towards clinical and commercial supply.”

Deborah Jones, CEO, Resyca said: “When developing nasal therapies, particularly for sensitive and complex formulations, the choice of delivery device can be just as important as the formulation itself. Our existing Ultra Soft Nasal Spray device has already demonstrated the value of soft mist sprays for nasal drug delivery. NasaDose Ultra Soft Unit Dose Spray brings that technology into a unit dose format, adding an option for therapies where a single dose is preferred or required.

Together, our multi dose and unit dose soft mist devices give developers more flexibility to choose a delivery system that suits their therapy and the needs of patients.”

Learn more at: https://bespak.com/platforms/nasadose-ultra-soft-unit-dose

About Bespak

Bespak is a specialist global contract development and manufacturing organisation (CDMO) solely focused on the inhaled and nasal drug delivery industry. It develops and manufactures inhaled and nasal drug products, drug delivery devices and components for the global pharmaceutical market. Headquartered in Holmes Chapel, UK, Bespak provides a specialist, fully integrated service to support customers from early-stage feasibility, analytical and formulation, product development and clinical supply, through to full-scale cGMP batch production.

Built on established expertise but ready for the future, Bespak is a long-term innovation partner committed to driving sustainability in the industry.  With expertise spanning pressurised Metered Dose Inhalers, Soft Mist Inhalers, and Dry Powder Inhalers for respiratory conditions, the company also specialises in intranasal drug delivery with device technologies, product development and manufacturing capabilities supporting liquid, powder and soft mist delivery platforms.  

Bespak will unveil its expanded nasal offering at CPHI 2026 in Milan, demonstrating how its new capabilities can support nasal drug products from development through to commercialisation. Visitors can meet the Bespak team at stand 11C27 to discuss their nasal development programmes.

More information: www.bespak.com

About Resyca

Resyca is redefining drug delivery with its next‑generation soft mist inhalers and soft nasal sprays. Founded in 2020 as a joint venture between Medspray and Bespak, Resyca develops advanced, proprietary delivery platforms that integrate Medspray’s micro‑nozzle technology.

With Resyca’s delivery devices, pharmaceutical partners can clearly differentiate their therapies through highly efficient pulmonary delivery and precise nasal administration — making Resyca’s platforms an excellent fit for a broad spectrum of drug-device combination products.

To further accelerate development and commercialisation, Resyca supports pharmaceutical partners with a comprehensive suite of services spanning early‑stage development through to full commercial launch.

More information: www.resyca.com

The post Bespak expands next-generation nasal offering with launch of NasaDose  first appeared on Resyca.

As CEO, Dr Jones will lead Resyca’s next phase of growth, expanding strategic collaborations with global pharmaceutical and biotech partners and advancing its soft mist inhaler and nasal spray platforms. Her focus will be on enabling more efficient, patient-friendly drug delivery and strengthening Resyca’s position as a trusted partner in integrated drug–device combination development.

Dr Jones brings more than 20 years of executive leadership experience driving commercial growth in life sciences technology companies. She has guided organisations through international expansion, strategic partnerships, and technology platform scaling to deliver sustained revenue growth. She joins Resyca from Proveris Scientific, where she led commercial strategy across EMEA and India and played a pivotal role in advancing the global adoption of aerosol and spray characterisation technologies. She is widely recognised for her expertise in understanding the complexities in inhalation and nasal drug development.

“I am excited to join Resyca at such a pivotal time in the evolution of inhaled and nasal drug delivery,” said Dr Jones. “Soft mist technologies represent a significant step forward in optimising drug deposition, improving ease of use, and enhancing dose consistency. With Resyca’s technologies, we can improve adherence, therapeutic effectiveness, and ultimately patient outcomes.”

About Resyca

Resyca® is redefining drug delivery with its next‑generation Soft Mist Inhalers and Soft Nasal Sprays. Founded in 2020 as a joint venture between Medspray and Bespak, Resyca develops advanced, proprietary delivery platforms that integrate Medspray’s micro‑nozzle technology.

With Resyca’s delivery devices, pharmaceutical partners can clearly differentiate their therapies through highly efficient pulmonary delivery and precise nasal administration—making Resyca’s platforms an excellent fit for a broad spectrum of drug–device combination products.

To further accelerate development and commercialisation, Resyca supports pharmaceutical partners with a comprehensive suite of services spanning early‑stage development through to full commercial launch.

To learn more, please visit www.resyca.com.

The post Resyca Announces the Appointment of Deborah Jones as New CEO first appeared on Resyca.

Read the fact sheet to learn more.

The post Resyca® Soft Nasal Spray Adaptor: low shear forces and optimal nasal coverage first appeared on Resyca.

Download our fact sheet to discover the key benefits of the PFSI Soft Mist Inhaler.

The post Resyca® PFSI™ Soft Mist Inhaler (SMI): Inhalation spray in a convenient device first appeared on Resyca.

Download our fact sheet to discover the key benefits of the Pulmospray™ Soft Mist Inhaler.

The post Resyca® Pulmospray™ Soft Mist Inhaler (SMI): fast preparation and breath-synchronised delivery first appeared on Resyca.

Publication: ONdrug Delivery 180, 26th November 2025

Abstract: With the increasing demand for new inhalation therapies, the need for efficient, patient-centric and sustainable delivery platforms is paramount. The Resyca PFSI is uniquely positioned to meet these needs, enabling precise and reliable delivery of even the most fragile molecules.

Soft Mist Inhaler (SMI) technology is transforming inhaled drug delivery — making treatments more efficient, patient-friendly, and sustainable.

Key highlights from the article:

• Enhanced Usability: SMIs reduce coordination errors and improve lung deposition, supporting better outcomes for diverse patient groups.
• Compatibility with Biologics: Ideal for next-generation therapies like vaccines and gene therapies, where gentle aerosolisation is crucial.
• Innovation with PFSI™: Resyca’s Pre-Filled Syringe Inhaler sets new standards for precision dosing, scalability, and patient-centric design. PFSI – Soft Mist Inhaler SMI.

This innovation is paving the way for tailored dosing, improved treatment adherence, and cost-effective delivery—critical for biologics and high-value therapies.

The post Enhancing drug delivery with innovative soft mist inhaler technology first appeared on Resyca.

Journal: European Journal of Pharmaceutical Sciences, Volume 214, 2025

Abstract: Inhalable mRNA is an emerging field holding great potential for applications as mucosal vaccination, antiviral therapy or protein replacement therapies, but efficient delivery remains a bottleneck.

In this study, we explore the use of a Soft Mist Inhaler (SMI), based on Rayleigh-breakup, for pulmonary mRNA delivery. We found that the SMI successfully aerosolised GFP mRNA encapsulated in liposomes while maintaining colloidal stability, mRNA integrity and in vitro transfection efficiency in A549 cells. Furthermore, the device enabled simultaneous delivery of nucleic acids in various sizes using a model CRISPR/Cas13d system.

The formulation could be reproducibly aerosolised with a low geometric standard deviation (GSD) and optimal aerosol droplet size for lung delivery. Based on the aerosol data, lung deposition modeling was conducted, indicating high lung deposition with minimal exhaled fraction. In comparison, aerosolization by a conventional Vibrating Mesh Nebuliser led to significant loss of nanoparticles and transfection efficiency. Utilising SMIs may facilitate pulmonary delivery of mRNA nanoparticle formulations by lowering stability-associated hurdles while providing intrinsically high deposition in the lungs.

Reference

The post Soft mist inhaler nebulisation by Rayleigh-breakup largely preserves functional integrity of liposomal mRNA in respirable aerosols first appeared on Resyca.

Resyca is a joint venture between Bespak and Medspray. Bespak has a strong franchise and is an established supplier of inhalation devices to the pharma industry.

By having access to this proprietary device manufacturing line, Resyca can provide shorter time lines for new customers. The idea is that multiple customers will use the same device manufacturing platform with minor pre designed change options like the volume per actuation and the outer parts design, including colours and labeling. This way Resyca can achieve economies of scale for the soft mist inhaler platform, for multiple clients who separately would not have enough unit sales to justify the capital investments necessary.

The post Bespak – device manufacturing first appeared on Resyca.

Journal: International Journal of Pharmaceutics, Volume 683, 2025

Abstract: The COVID-19 pandemic has emphasised the need for innovative and efficient drug delivery systems, particularly for nucleic acid-based therapeutics.

Lipid nanoparticle (LNP)-based small interfering RNA (siRNA) technology provides a promising strategy for gene therapy, immune modulation, and targeted molecular medicine. Intranasal delivery of LNP-siRNA formulations offers advantages such as efficient gene silencing and non-invasive administration.

However, the nasal spray device plays a crucial role in determining the deposition patterns within the nasal cavity and can impact the physicochemical stability of LNP formulations during aerosolisation. In this study, the Rayleigh Jet Nasal Atomiser was evaluated for its performance in delivering three LNP-siRNA formulations designed based on the LNP structures of Moderna, Pfizer, and Alnylam (Onpattro) marketed formulations, respectively.

Key nanoparticle characteristics, including particle size distribution, polydispersity index (PDI), zeta potential, and encapsulation efficiency, as well as aerosol properties such as droplet size, were analyzed before and after aerosolisation. Deposition patterns were assessed using the Alberta Idealized Nasal Inlet (AINI) model to determine the distribution of aerosolized LNPs. The results demonstrate that the Rayleigh Jet Nasal Atomizer efficiently delivers all the three formulations to the nasal cavity, primarily targeting the nasopharynx, while minimizing deposition in the lower respiratory tract.

Additionally, the device maintained LNPs structural integrity, although a reduction in encapsulated siRNA concentration suggests partial LNP disruption during aerosolisation. These findings indicate that the Rayleigh Jet Nasal Atomiser is a suitable device for intranasal delivery of LNP-based siRNA therapeutics, offering a promising approach for nasal administration of RNA-based drug delivery.

Reference

The post Evaluation of Rayleigh jet atomiser for intranasal delivery of lipid nanoparticle – siRNA formulations: stability, deposition, and device performance first appeared on Resyca.

Journal: Journal of Drug Delivery Science and Technology, Volume 115, Part 1, 2026

Abstract: Pulmonary delivery of mRNA-lipid nanoparticles (mRNA-LNPs) offers a promising non-invasive route of administration for pulmonary gene therapy, vaccine applications, amongst others.

However, aerosolisation can compromise nanoparticle stability, affecting its payload and thus delivery efficiency. This study evaluates the impact of aerosolisation via Rayleigh breakup and Savart impinging jet-based SMIs and various mesh nebulisers in preserving mRNA-LNP integrity and thus optimising pulmonary deposition.

The PFSI (Resyca) and Respimat (Boehringer Ingelheim) SMIs, as well as the Innospire Go and Pari eFlow mesh nebulisers were assessed for their impact on LNP particle size, zeta potential, encapsulation efficiency, and mRNA stability.

The PFSI SMI maintained mRNA-LNP physicochemical properties with minimal aggregation and superior encapsulation efficiency, while the other devices induced significant particle alterations and mRNA degradation.

These findings highlight the potential of SMIs, particularly the PFSI device, for inhaled mRNA-LNP delivery. Its ability to maintain nanoparticle stability warrants clinical evaluation.

Reference

The post Rayleigh-based soft mist inhalers preserve mRNA-LNP integrity for pulmonary delivery first appeared on Resyca.